Diversity action plans: Stakeholders seek clarity on demographic data, enrollment, and global trials
Regulatory NewsJeff Craven
Clinical TrialsDiversityGuidanceMedical DevicesPharmaceuticalsUnited StatesUS Food and Drug Administration (FDA)Regulatory NewsJeff CravenClinical TrialsDiversityGuidanceMedical DevicesPharmaceuticalsUnited StatesUS Food and Drug Administration (FDA)